Core Viewpoint - The company is committed to the inheritance and innovation of traditional Chinese medicine, actively advancing the research and development of innovative traditional Chinese medicine products and the secondary development of key varieties [1] Group 1: R&D Initiatives - The company is focusing on the modernization of classic formulas in the chronic disease field [1] - The company is exploring partnerships with research institutions in the classic formula area to promote project collaboration [1] Group 2: Strategic Partnerships - The company has established a strategic cooperation with Shantou University Medical College to jointly conduct new drug development and related basic and clinical research [1] - This partnership aims to accelerate the progress of innovative traditional Chinese medicine research and development [1]

每经AI快讯，有投资者在投资者互动平台提问：你好董秘，公司在中药创新药有什么进展？ 粤万年青（301111.SZ）9月24日在投资者互动平台表示，公司始终致力于中药的传承与创新，目前正积 极推进中药创新药的研发与重点品种的二次开发，如慢病领域的经典名方现代化改造，同时积极考察经 典名方领域的研发机构以推进项目合作，不断夯实未来创新药战略布局的基础。公司已与汕头大学医学 院达成战略合作，双方将共同开展新药开发、药物相关基础与临床研究等工作，加速推动中药创新药的 研发进展。敬请关注公司后续相关公告。 （记者 胡玲） ...

中药配方颗粒业务尚处起步，稳步推进拓展 盘龙药业于2025年9月18日通过线上交流会的形式，接受了华福证券、华创证券、农银基金等3家机构的 调研。公司董事长谢晓林先生、证券事务代表赵晓妮及投资者关系管理经理梁馨方参与接待，就中药配 方颗粒业务、中药创新药进展、分红政策及基层市场开发策略等投资者关心的问题进行了交流。 在谈及中药配方颗粒业务何时能成为第二增长曲线时，盘龙药业表示，已于2024年年末完成中药配方颗 粒智能化生产线建设，并成立业务发展中心。截至目前，累计完成研发备案上市品种数达310个，在18 个省份完成挂网备案。该业务现阶段以陕西省为中心，逐步向外拓展业务覆盖范围。 创新药研发多点开花，梯度布局推进 对于中药创新药的进展，公司透露，中药改良型新药PL JT004已进入CDE临床受理阶段；化学仿制药 PL-JT001完成BE试验待报产；化学仿制药（PLJT - 002/003）年内启动IND申报；1.1类中药创新药 PLZY - 001/PL - XP013/PL - XP012分阶段推进临床前及II期工作。公司通过梯度化管线布局推 动"21355"大品种培育目标，构建立体产品生态，提升产品核心竞争 ...

Core Viewpoint - The company reported a robust performance in the first half of 2025, with significant revenue growth and improved profit quality, driven primarily by the sales increase in traditional Chinese medicine products [1][2]. Group 1: Financial Performance - The company achieved total revenue of 574 million yuan, representing a year-on-year increase of 26.06%, with the traditional Chinese medicine segment contributing significantly [1]. - Revenue from traditional Chinese medicine pieces surged to 123 million yuan, marking a dramatic increase of 380.89% [1]. - The self-produced traditional Chinese medicine segment generated 319 million yuan, accounting for 55.5% of total revenue, with a year-on-year growth of 2.29% [1]. - The net profit attributable to shareholders reached 60 million yuan, reflecting a growth of 0.81%, while the net profit excluding non-recurring items was 53 million yuan, up by 4.19% [1]. Group 2: Market Position and Product Development - The company's leading product, Panlong Qipian, holds a market share of 7.73% in the traditional Chinese medicine market for musculoskeletal and rheumatic diseases in public hospitals [1]. - The product has been included in 8 national clinical guidelines and 4 expert consensus documents, enhancing its clinical value [1]. Group 3: Research and Development - The company increased its R&D investment to 16 million yuan, a rise of 11.13%, focusing on three major pipelines, including innovative traditional Chinese medicines and chemical generic drugs [2]. - The company has initiated clinical research for several new drugs and is progressing with technology transfer and process validation [2]. - The company has established a new "Expert Workstation" in Shaanxi Province and has strengthened its "industry-university-research" collaboration through various national and provincial technology platforms [3]. Group 4: Intellectual Property and Market Expansion - The company holds a total of 79 patents, including 36 authorized invention patents and 43 design patents, with ongoing efforts to enhance its innovation capabilities [3]. - The company has completed the development filing for 310 varieties of traditional Chinese medicine formula granules, laying a foundation for future market expansion [3].

8月22日，苏州玉森新药开发有限公司与四川省现代中药创新技术有限公司在苏州正式签署产品合作协 议，宣布就"消腺止鼾口服液"与"天丹定眩颗粒"两大中药1.1类创新药展开深度合作，并隆重举行签约 仪式。此次合作标志着双方在中医药创新领域迈出关键步伐，将共同推动中药新药研发与产业化进程。 消腺止鼾口服液针对儿童腺样体肥大，以桔梗、鱼腥草等组方清热化痰、调畅气机，临床定位3—7岁痰 热内蕴患儿，兼具疗效与安全性，填补中成药市场空白。天丹定眩颗粒由经典名方化裁而成，专注风痰 上扰型眩晕症的治疗，以天麻、丹参为核心，兼具化痰息风与活血通络之效，满足老龄化趋势下眩晕治 疗需求。两产品均以创新处方和临床优势，分别瞄准40亿腺样体肥大及12亿眩晕市场，体现中药"标本 兼治、副作用小"的特色，预计2026年陆续进入临床，为儿科与慢病领域提供安全高效的新选择。 玉森新药董事长玄振玉教授指出："此次合作不仅是技术与产业的结合，更是跨区域创新生态的协同。 我们将基于玉森新药中药创新药现代化研究的深厚积累，以及四川省现代中药创新技术公司的产业化优 势，共同构建从实验室研究到临床应用的完整创新闭环。" 四川省现代中药创新技术有限公司董事长 ...

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd., received approval for clinical trials of the innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [1][6]. Group 1: Drug Information - The drug Ziying Granules is classified as a Class 1.1 traditional Chinese medicine and is intended for clinical trials to treat chronic pelvic pain resulting from pelvic inflammatory disease [1][2]. - The cumulative R&D investment for this drug project is approximately 8.4717 million yuan (about 1.2 million USD) as of the announcement date [3]. Group 2: Market Situation - The market for traditional Chinese medicine in gynecological diseases has shown stability, with sales remaining around 5.7 billion yuan from 2020 to 2023, and a growth rate of 3.38% in the first three quarters of 2024 [4]. - The market share for gynecological regulation drugs is 47.38%, with a year-on-year sales growth of 6.61%, while gynecological inflammation drugs account for 35.02% of the market, with a slight decline in sales by 1.75% [4]. - The demand for drugs treating chronic pelvic pain is significant, with various existing products in the market, including Fuke Qianjin Tablets and Guizhi Fuling Capsules, which have notable sales figures [4][5]. Group 3: Approval Process - Following the receipt of the clinical trial approval, Fangsheng R&D will conduct the necessary clinical trials and compile the application materials for product registration and market launch [6].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its subsidiary, GuangDong Fangsheng R&D Pharmaceutical Co., Ltd., received approval for clinical trials of its innovative traditional Chinese medicine, Ziying Granules, aimed at treating chronic pelvic pain due to pelvic inflammatory disease [2][3]. Drug Information - Drug Name: Ziying Granules - Dosage Form: Granule - Registration Category: Traditional Chinese Medicine Class 1.1 - Application Matter: Clinical Trials - Acceptance Number: CXZL2500030 - Approval Conclusion: The clinical trial application for Ziying Granules was accepted on May 22, 2025, and is approved to proceed with trials for chronic pelvic pain [2][3]. New Drug Details - Ziying Granules are based on clinical experience for treating pelvic inflammatory disease and are intended for chronic pelvic pain with symptoms including lower abdominal pain, lumbar discomfort, and abnormal discharge [3]. Market Situation for Similar Drugs - The market for traditional Chinese medicine in gynecological diseases has maintained sales around 5.7 billion yuan from 2020 to 2023, with a growth rate of 3.38% in the first three quarters of 2024. The market share for gynecological regulation drugs is 47.38%, with a year-on-year sales increase of 6.61% [3]. - The demand for drugs treating pelvic inflammatory disease is significant, with over 3.2 billion yuan in sales for traditional Chinese medicine gynecological drugs in urban pharmacies in the first three quarters of 2024, despite a 6.40% year-on-year decline [3]. Competitor Products - Current treatments for chronic pelvic pain include various products such as Fuke Qianjin Tablets/Capsules, Guizhi Fuling Capsules/Pills/Tabs, and others, with sales data indicating significant market presence [4][5].

Group 1 - The core point of the article is that Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng R&D Pharmaceutical Co., Ltd. (referred to as "Fangsheng R&D"), has received the clinical trial approval notice from the National Medical Products Administration for its innovative traditional Chinese medicine project, Ziying Granules [1] - The Ziying Granules are developed based on years of clinical experience in treating pelvic inflammatory disease and are specifically aimed at addressing chronic pelvic pain as a sequela of pelvic inflammatory disease [1] - The symptoms targeted by the Ziying Granules include lower abdominal pain, lumbar and sacral discomfort, increased vaginal discharge with yellow and thick characteristics, fluctuating low fever, exacerbated abdominal pain during menstruation, chest tightness, poor appetite, dry mouth, loose stools or constipation, and yellowish urine [1]

Group 1 - The core point of the article is that Fangsheng Pharmaceutical's subsidiary, Fangsheng R&D, has received approval from the National Medical Products Administration for the clinical trial of its innovative traditional Chinese medicine, Ziying Granules [1] - Ziying Granules is classified as a Class 1 innovative traditional Chinese medicine and has not yet been launched in domestic or international markets as of the announcement date [1] - The product is developed based on years of clinical experience in treating pelvic inflammatory disease and is specifically aimed at alleviating chronic pelvic pain associated with pelvic inflammatory disease sequelae [1]

Transaction Overview - The company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025, for the acquisition of a Class 1 new Chinese medicine "Chaiqin Ning Shen Granules" for RMB 22 million [2] - This transaction does not constitute a related party transaction and falls within the chairman's authorization scope, thus does not require board or shareholder approval [2] Counterparty Information - Shanxi Traditional Chinese Medicine Research Institute, established in 1957, is one of the earliest TCM research institutions in China, integrating medical care, research, teaching, and industry [3] - The institute has undertaken over 1,033 research projects and has received numerous awards, including 15 national new drug approvals and 31 authorized invention patents [3] Target Transaction Details - The transfer includes the clinical trial approval notice and related patents for "Chaiqin Ning Shen Granules" [4] - The granules are indicated for liver qi stagnation and anxiety-related insomnia, showing significant improvement in symptoms [5] Market Context - According to a report by the China Sleep Research Society, 48.5% of adults in China experience sleep difficulties, with a growing prevalence of insomnia-related anxiety [6] - The insomnia medication market in China grew from RMB 9.84 billion in 2016 to RMB 11.7 billion in 2020, with projections of RMB 15.12 billion and RMB 21.19 billion by 2025 and 2030, respectively [6] Agreement Details - The agreement stipulates that the company will pay a total of RMB 22 million, with payments tied to specific milestones in the drug development process [12] - The agreement includes provisions for the transfer of all relevant technical materials and responsibilities for both parties in the development process [8][9] Impact on the Company - The acquisition of the clinical trial approval and patent rights for "Chaiqin Ning Shen Granules" is expected to enhance the company's R&D pipeline for innovative Chinese medicines, improving its core competitiveness and sustainable development [16] - The agreement's implementation may take time, and it is not expected to have a significant short-term impact on the company's operating performance [16]